BR112016013425A2 - Composto e composição farmacêutica - Google Patents

Composto e composição farmacêutica

Info

Publication number
BR112016013425A2
BR112016013425A2 BR112016013425A BR112016013425A BR112016013425A2 BR 112016013425 A2 BR112016013425 A2 BR 112016013425A2 BR 112016013425 A BR112016013425 A BR 112016013425A BR 112016013425 A BR112016013425 A BR 112016013425A BR 112016013425 A2 BR112016013425 A2 BR 112016013425A2
Authority
BR
Brazil
Prior art keywords
gamma
ror
compound
pharmaceutical composition
compounds
Prior art date
Application number
BR112016013425A
Other languages
English (en)
Inventor
Das Sanjib
Sundarlal Chaudhari Sachin
Thomas Abraham
Ramesh Pardeshi Shailesh
Govindrao Deshmukh Vishal
Dilip Wadekar Prashant
Khairatkar-Joshi Neelima
Manish Shah Daisy
Bajpai Malini
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of BR112016013425A2 publication Critical patent/BR112016013425A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSTO E COMPOSIÇÃO FARMACÊUTICA. A presente revelação está direcionada a compostos de fórmula (I) e sais farmaceuticamente aceitáveis dos mesmos, em que X, X(1), M, R(2), R(3), R(4), R(5), m, n e p são conforme definido no presente documento, que são ativos como moduladores de receptor órfão relacionado a retinoide gama t (ROR(Gama)t). Esses compostos previnem, inibem ou suprimem a ação de ROR(Gama)t e são, portanto, úteis no tratamento de doenças, distúrbios, síndromes ou afecções mediadas por ROR(Gama)t, tais como, por exemplo, dor, inflamação, DPOC, asma, artrite reumatoide, colite, esclerose múltipla, doenças neurodegenerativas e câncer.
BR112016013425A 2013-12-10 2014-12-09 Composto e composição farmacêutica BR112016013425A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3853MU2013 2013-12-10
IN527MU2014 2014-02-14
IN2172MU2014 2014-07-04
PCT/IB2014/066720 WO2015087234A1 (en) 2013-12-10 2014-12-09 Bicyclic heteroaryl indole analogues useful as ror gamma modulators

Publications (1)

Publication Number Publication Date
BR112016013425A2 true BR112016013425A2 (pt) 2017-08-08

Family

ID=52355020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013425A BR112016013425A2 (pt) 2013-12-10 2014-12-09 Composto e composição farmacêutica

Country Status (18)

Country Link
US (1) US9682977B2 (pt)
EP (1) EP3080090B1 (pt)
JP (1) JP2016539989A (pt)
CN (1) CN105980364A (pt)
AP (1) AP2016009281A0 (pt)
AU (1) AU2014363035A1 (pt)
BR (1) BR112016013425A2 (pt)
CA (1) CA2933003A1 (pt)
CL (1) CL2016001441A1 (pt)
EA (1) EA029489B1 (pt)
IL (1) IL246123A0 (pt)
MX (1) MX2016007604A (pt)
PE (1) PE20160687A1 (pt)
PH (1) PH12016501105A1 (pt)
SG (1) SG11201604714SA (pt)
TW (1) TW201605797A (pt)
WO (1) WO2015087234A1 (pt)
ZA (1) ZA201604454B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2017051319A1 (en) * 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2017075182A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
EP3650448A4 (en) * 2017-07-06 2021-03-31 Jiangsu Hengrui Medicine Co., Ltd. INDOLE-FORMAMIDE, PROCESS OF PREPARATION AND USE IN MEDICINE
US11466024B2 (en) 2017-08-01 2022-10-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicylic compound acting as an inhibitor
WO2019100106A1 (en) * 2017-11-24 2019-05-31 The University Of Sydney Antibacterial compounds and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621237A (en) 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
US7781479B2 (en) * 2005-01-14 2010-08-24 Dainippon Sumitomo Pharma Co., Ltd. Heteroaryl derivatives
EP2606031B1 (en) * 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
CA2816753A1 (en) * 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator

Also Published As

Publication number Publication date
AU2014363035A1 (en) 2016-06-30
WO2015087234A1 (en) 2015-06-18
CA2933003A1 (en) 2015-06-18
CN105980364A (zh) 2016-09-28
US20160326163A1 (en) 2016-11-10
TW201605797A (zh) 2016-02-16
IL246123A0 (en) 2016-08-02
PE20160687A1 (es) 2016-08-11
PH12016501105A1 (en) 2016-07-11
SG11201604714SA (en) 2016-07-28
EA201691002A1 (ru) 2016-12-30
EA029489B1 (ru) 2018-04-30
ZA201604454B (en) 2017-11-29
EP3080090B1 (en) 2018-01-31
US9682977B2 (en) 2017-06-20
MX2016007604A (es) 2017-02-28
CL2016001441A1 (es) 2017-03-03
JP2016539989A (ja) 2016-12-22
AP2016009281A0 (en) 2016-06-30
EP3080090A1 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
BR112016013425A2 (pt) Composto e composição farmacêutica
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
BR112018001469A2 (pt) composto, composição farmacêutica e uso de um composto
WO2013171729A3 (en) Aryl and heteroaryl amide compounds as ror gamma t modulator
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
EA201591532A1 (ru) Ингибиторы carm1 и их применение
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112014011938A2 (pt) combinação de formulação de dois compostos antivirais
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112014030795A2 (pt) composto, composição farmacêutica, uso de um composto e processo para preparação de um composto
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
PH12014502524B1 (en) Carboxylic acid compounds
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
MX2017015741A (es) Moduladores de ror gamma (ror?).
BR112016022519A2 (pt) Cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase, seus usos, e composição farmacêutica
MX2017015739A (es) Moduladores de ror gamma (ror?).
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
EA201600394A1 (ru) Трициклические соединения пиперидина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]